News & Updates

New drug applications approved by US FDA as of 16-31 January 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), the addition of tiragolumab to atezolizumab plus bevacizumab yields meaningful improvements in antitumour response and disease control, according to data from an open-label phase 1b–2 study.

The disease-free survival outcome in patients with low rectal cancer who receive laparoscopic surgery compares favourably with that in those who receive open surgery, according to a study.

The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.

High-fibre diets improved blood cancer outcomes in two studies reported at ASH 2024. 

In patients with clinically node-negative, T1 or T2 invasive breast cancer, omission of axillary staging does not appear to have a negative impact on disease–free survival, according to the results of the INSEMA trial.